Home Newsfeeds William Blair Downgrades Avalara to Market Perform

William Blair Downgrades Avalara to Market Perform

William Blair analyst Bhavan Suri downgrades Avalara (NYSE:AVLR) from Outperform to Market Perform.

byBenzinga Newsdesk

August 24, 2022

1 minute read

William Blair analyst Bhavan Suri downgrades Avalara (NYSE:AVLR) from Outperform to Market Perform.

What’s Gaining Popularity Among US Teens Battling Obesity? Novo Nordisk’s Weight Loss Drug Wegovy

By Vandana Singh

February 15, 10:05 AM

Rise of adolescent usage of Novo Nordisk's Wegovy for pediatric obesity. Surging demand among families, but concerns linger on the impact of weight-loss drugs on growing children's development.

LLY

Analyst Ratings

What 5 Analyst Ratings Have To Say About Bath & Body Works

By Benzinga Insights

January 6, 1:00 PM

Analysts have provided the following ratings for Bath & Body Works (NYSE:BBWI) within the last quarter: Bullish Somewhat…

BBWI

QuidelOrtho Receives CLIA Waiver For Sofia 2 SARS Antigen+ FIA

By Benzinga Newsdesk

September 21, 4:08 PM

QuidelOrtho Corporation (NASDAQ:QDEL)("QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it

QDEL

News

Sana Biotechnology Prices Upsized Public Offering Of 17,272,728 Common Shares At $5.50/Share

By Benzinga Newsdesk

February 8, 3:51 AM

Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has priced its underwritten upsized public offering of 17,272,728

SANA

William Blair Downgrades Avalara to Market Perform

Related Posts

What’s Gaining Popularity Among US Teens Battling Obesity? Novo Nordisk’s Weight Loss Drug Wegovy

What 5 Analyst Ratings Have To Say About Bath & Body Works

QuidelOrtho Receives CLIA Waiver For Sofia 2 SARS Antigen+ FIA

Sana Biotechnology Prices Upsized Public Offering Of 17,272,728 Common Shares At $5.50/Share